Quantitative analysis of the CD4⁺ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay

• Heidi S. Schultz ,

  * E-mail: HSHZ@novonordisk.com

  Affiliation Immunogenicity Prediction and Tolerance, Global Research, Novo Nordisk A/S, Måløv, Denmark

  http://orcid.org/0000-0002-2679-9290

  ⨯
• Stine Louise Reedtz-Runge,

  Affiliation NCD Project Management, Global Research, Novo Nordisk A/S, Måløv, Denmark

  ⨯
• B. Thomas Bäckström,

  Current address: BTB Pharma AB, Malmö, Sweden

  Affiliation Immunogenicity Prediction and Tolerance, Global Research, Novo Nordisk A/S, Måløv, Denmark

  ⨯
• Kasper Lamberth,

  Affiliation Immunogenicity Prediction and Tolerance, Global Research, Novo Nordisk A/S, Måløv, Denmark

  ⨯
• Christian R. Pedersen,

  Affiliation Immunogenicity Assessment, Global Research, Novo Nordisk A/S, Måløv, Denmark

  ⨯
• Anne M. Kvarnhammar,

  Affiliation Immunogenicity Prediction and Tolerance, Global Research, Novo Nordisk A/S, Måløv, Denmark

  ⨯
• on behalf of the ABIRISK consortium

  ¶¶ The complete membership of the author group can be found in the Acknowledgments.

  ⨯